The IMPACT-SIRIO 5 is a randomized, double-blind, phase III clinical trial evaluating the safety and efficacy of PCSK9 inhibition on clinical outcome (need for intubation, death of any cause, and changes in IL-6 concentrations) in patients during the acute inflammatory stage of COVID-19 (21). The gene discussed is IL6; the disease is COVID-19.